Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cells of the Adaptive Immune Response01:23

Cells of the Adaptive Immune Response

4.5K
The T and B lymphocytes of the adaptive immune system develop from common lymphoid progenitor cells in the bone marrow. These progenitors give rise to precursors that eventually develop into both T and B lymphocytes. As these precursors mature, they gain the ability to detect and respond to foreign antigens in the body, a process known as immunocompetence. Additionally, these precursors acquire self-tolerance, a process that ensures they do not react to self-antigens. This intricate system...
4.5K
B Cell Activation and Differentiation01:24

B Cell Activation and Differentiation

6.5K
The adaptive immune response, a sophisticated defense mechanism, relies on the activation and differentiation of B lymphocytes, or B cells. These processes enable our bodies to mount a tailored response against specific pathogens such as bacteria, free virus particles, toxins, and parasites.
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
6.5K
Cell-mediated Immune Responses01:40

Cell-mediated Immune Responses

73.5K
Overview
73.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Development of a Disease Activity Index for the Assessment of VEXAS Syndrome (VEXAS-DAI).

Arthritis care & research·2026
Same author

Evaluation of pregnancy outcomes in patients with rheumatoid arthritis compared with the general population: results from a French national prospective and matched study.

RMD open·2026
Same author

Prospective study on the [<sup>18</sup>F]FDOPA PET/CT role in the management of medullary thyroid cancer patients with high residual calcitonin level after surgery.

European journal of nuclear medicine and molecular imaging·2026
Same author

Paediatric-onset autoimmune cytopenia: How can we reduce the long-term mortality?

British journal of haematology·2026
Same author

Exploring glucocorticoid dose-response patterns in VEXAS syndrome: a pilot retrospective study.

Rheumatology international·2026
Same author

Post-Exertional Malaise in Post-COVID-19 Syndrome: A Shift in the Frequency Across Pandemic Phases.

Journal of clinical medicine·2026

Related Experiment Video

Updated: Sep 16, 2025

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

17.8K

Durable Responses With Front-Line Rituximab in Autoimmune Cytopenias Associated With Indolent B-Cell Clones.

Yoann Zadro1, Amélie Lusque2, Héloïse Rey3

  • 1Department of Internal Medicine, IUCT-Oncopole-Toulouse University Hospital, Toulouse University, Toulouse, France.

American Journal of Hematology
|July 8, 2025
PubMed
Summary

Front-line rituximab provides durable responses for autoimmune cytopenias linked to indolent B-cell clones. This treatment offers a promising therapeutic strategy for these rare conditions.

Keywords:
B‐cell lymphomaautoimmune hemolytic anemiachronic lymphocytic leukemiaimmune thrombocytopeniarituximab

More Related Videos

Assessment of Human Natural Killer Cell Events Driven by Fc&#947;RIIIa Engagement in the Presence of Therapeutic Antibodies
09:54

Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies

Published on: May 22, 2020

3.6K
Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.5K

Related Experiment Videos

Last Updated: Sep 16, 2025

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

17.8K
Assessment of Human Natural Killer Cell Events Driven by Fc&#947;RIIIa Engagement in the Presence of Therapeutic Antibodies
09:54

Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies

Published on: May 22, 2020

3.6K
Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.5K

Area of Science:

  • Hematology
  • Immunology
  • Oncology

Background:

  • Autoimmune cytopenias (AICs) can be associated with indolent B-cell lymphoid malignancies.
  • Rituximab, an anti-CD20 monoclonal antibody, is a standard treatment for various B-cell disorders.

Discussion:

  • This study investigates the efficacy of first-line rituximab in patients with AICs and indolent B-cell clones.
  • Assessing response rates and durability is crucial for understanding treatment benefits.

Key Insights:

  • Front-line rituximab demonstrates durable responses in patients with autoimmune cytopenias.
  • The presence of indolent B-cell clones may predict a favorable response to rituximab therapy.

Outlook:

  • Further research can explore long-term outcomes and optimal treatment duration.
  • Rituximab may represent a valuable therapeutic option for managing these specific AICs.